CF Acquisition Corp. VI(CFVI)

$12.04▲0.42 (3.61%)

CF Acquisition Corp. VI(CFVI)

$12.04▲0.42 (3.61%)

$12.04

+3.61%(+0.42)

Previous Close

Latest Volume

Previous Volume

52 Week High

Dividend Yield

Extended Price

Extended Change

Extended Change %

52W Range9.67

Want to monitor CFVI?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Gross Margin

Operating Margin

Revenue Growth

No description available.

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

$12.04

Alerts

News

IT Investors Have Opportunity to Lead Gartner, Inc. Securities Fraud Lawsuit

Rosen Law Firm Encourages SYLA Technologies Co., Ltd. Investors to Inquire About Securities Class Action Investigation - SYT

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

Micron Could Be The Next Intel

DOOR Deadline: DOOR Investors Have Opportunity to Lead Masonite International Corporation Securities Fraud Lawsuit

U.S. IPO Weekly Recap: SpaceX Confidentially Files, Energy Play Goes Public, And More Defense Tech Joins The IPO Pipeline

JEPI vs. JEPQ: Which Is the Better Buy in April?

Meta paused its work with AI training startup Mercor after a data breach

DoubleVerify: Strong Retention, Attractive Valuation

Phoenix Education Partners: A Top Tier Play In For-Profit Education

KKR: Still A Growth Story Despite Credit Fears

This Under-the-Radar Fintech Stock Has Been Quietly Gaining Market Share

PAYSAFE DEADLINE: ROSEN, A NATIONALLY RECOGNIZED INVESTOR RIGHTS LAW FIRM, Encourages Paysafe Limited Investors with Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action - PSFE

Dividends Don't Lie: This Is the Most Reliable High-Yield REIT

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit

Foundation for a Drug-Free World Volunteers Reach Athletes and Communities Across Italy During 2026 Winter Olympics

INVESTOR DEADLINE: Eos Energy Enterprises, Inc. (EOSE) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

QLV: Sensible Quality And Low Volatility Strategy, Yet Outperformance Is Unlikely, A Hold

MBS: Mortgages Are Attractive After The Sell-Off

ANI Pharmaceuticals: Worthy Of A Position

About

Explore More

IT Investors Have Opportunity to Lead Gartner, Inc. Securities Fraud Lawsuit

Rosen Law Firm Encourages SYLA Technologies Co., Ltd. Investors to Inquire About Securities Class Action Investigation - SYT

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

Micron Could Be The Next Intel

DOOR Deadline: DOOR Investors Have Opportunity to Lead Masonite International Corporation Securities Fraud Lawsuit

U.S. IPO Weekly Recap: SpaceX Confidentially Files, Energy Play Goes Public, And More Defense Tech Joins The IPO Pipeline

JEPI vs. JEPQ: Which Is the Better Buy in April?

Meta paused its work with AI training startup Mercor after a data breach

DoubleVerify: Strong Retention, Attractive Valuation

Phoenix Education Partners: A Top Tier Play In For-Profit Education

KKR: Still A Growth Story Despite Credit Fears

This Under-the-Radar Fintech Stock Has Been Quietly Gaining Market Share

PAYSAFE DEADLINE: ROSEN, A NATIONALLY RECOGNIZED INVESTOR RIGHTS LAW FIRM, Encourages Paysafe Limited Investors with Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action - PSFE

Dividends Don't Lie: This Is the Most Reliable High-Yield REIT

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit

Foundation for a Drug-Free World Volunteers Reach Athletes and Communities Across Italy During 2026 Winter Olympics

INVESTOR DEADLINE: Eos Energy Enterprises, Inc. (EOSE) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

QLV: Sensible Quality And Low Volatility Strategy, Yet Outperformance Is Unlikely, A Hold

MBS: Mortgages Are Attractive After The Sell-Off

ANI Pharmaceuticals: Worthy Of A Position

$12.04